This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pregabalin In Partial Seizures Extension Study (PREPS EXT)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: August 31, 2005
Last updated: March 4, 2015
Last verified: March 2015
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.

Condition Intervention Phase
Seizures Drug: Pregabalin Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Reduction in seizure frequency. [ Time Frame: 18 months ]

Secondary Outcome Measures:
  • Seizure-free patients during each 3-month period [ Time Frame: 18 Months ]
  • Responder Rate 50% during each 3-month period (proportion of patients with 50% or greater reduction of seizures). [ Time Frame: 18 Months ]
  • Responder rate 75% during each 3-month period (proportion of patients with 75% or greater reduction of seizures). [ Time Frame: 18 Months ]

Enrollment: 227
Study Start Date: April 2005
Study Completion Date: September 2007
Arms Assigned Interventions
Experimental: Single Arm Drug: Pregabalin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • met the inclusion/exclusion criteria for A0081005
  • have completed the 21-week study and have shown a significant clinical response and wish to continue treatment

Exclusion Criteria:

  • Having a treatable cause of seizure.
  • Having a progressive neurological or systemic disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143130

  Show 47 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Clinical Trials Disclosure Group, Pfizer, Inc. Identifier: NCT00143130     History of Changes
Other Study ID Numbers: A0081015
Study First Received: August 31, 2005
Last Updated: March 4, 2015

Keywords provided by Pfizer:
phase 4, open label, seizures, epilepsy, add-on therapy, pregabalin, lyrica

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on July 27, 2017